Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 5
Submit an article Journal homepage
1,316
Views
0
CrossRef citations to date
0
Altmetric
Editorial

PARP Inhibition in Castration-Resistant Prostate Cancer

Lucia Nappi1 Vancouver Prostate Centre & Department of Urologic Science, University of British Columbia, Vancouver, British Columbia, Canada
&
Martin E Gleave1 Vancouver Prostate Centre & Department of Urologic Science, University of British Columbia, Vancouver, British Columbia, CanadaCorrespondence[email protected]
Pages 577-580 | Received 15 Dec 2015, Accepted 04 Jan 2016, Published online: 21 Jan 2016

References

  • American Cancer Society . Cancer Facts & Figures2015. www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
  • Sridhar SS , FreedlandSJ, GleaveMEet al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur. Urol.65(2), 289–299 (2014).
  • Beltran H , EngK, MosqueraJMet al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol.1(4), 466–474 (2015).
  • Wyatt AW , GleaveME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol. Med.7(7), 878–894 (2015).
  • Underhill C , ToulmondeM, BonnefoiH. A review of PARP inhibitors: from bench to bedside. Ann. Oncol.22(2), 268–279 (2011).
  • Do K , ChenAP. Molecular pathways: targeting PARP in cancer treatment. Clin. Cancer Res.19(5), 977–984 (2013).
  • Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol.26(22), 3785–3790 (2008).
  • Murai J , HuangSY, DasBBet al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.72(21), 5588–5599 (2012).
  • Brenner JC , AteeqB, LiYet al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell19(5), 664–678 (2011).
  • Chatterjee P , ChoudharyGS, SharmaAet al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2–ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE8(4), e60408 (2013).
  • Fong PC , BossDS, YapTAet al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
  • Castro E , GohC, OlmosDet al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol.31(14), 1748–1757 (2013).
  • Kaufman B , Shapira-FrommerR, SchmutzlerRKet al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol.33(3), 244–250 (2015).
  • Sandhu SK , OmlinA, HylandsLet al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann. Oncol.24(5), 1416–1418 (2013).
  • Robinson D , Van AllenEM, WuYMet al. Integrative clinical genomics of advanced prostate cancer. Cell161(5), 1215–1228 (2015).
  • Pitroda SP , PashtanIM, LoganHLet al. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci. Transl. Med.6(229), 229ra242 (2014).
  • Sandhu SK , SchelmanWR, WildingGet al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a Phase 1 dose-escalation trial. Lancet Oncol.14(9), 882–892 (2013).
  • Mateo J , CarreiraS, SandhuSet al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med.373(18), 1697–1708 (2015).
  • Azad AA , VolikSV, WyattAWet al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res.21(10), 2315–2324 (2015).
  • Gorodnova TV , SokolenkoAP, IvantsovAOet al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett.369(2), 363–367 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.